Affinity Investment Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Affinity Investment Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-44,903	Closed	-$6.34M	–	165
2016 Q2	$6.34M	Buy	44,903 +18,793	+72%	+$2.77M	0.47%	73
2016 Q1	$3.41M	Buy	26,110 +60	+0.2%	+$7.47K	0.3%	74
2015 Q4	$3.66M	Buy	26,050 +5,060	+24%	+$701K	0.31%	75
2015 Q3	$2.79M	Sell	20,990 -8,810	-30%	-$1.52M	0.25%	97
2015 Q2	$5.25M	Sell	29,800 -5,300	-15%	-$952K	0.42%	77
2015 Q1	$6.07M	Buy	35,100 +10,470	+43%	+$1.8M	0.44%	76
2014 Q4	$4.03M	Hold	24,630	–	–	0.37%	77
2014 Q3	$3.96M	Buy	+24,630	New	+$3.79M	0.4%	74

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Affinity Investment Advisors's JAZZ Position: Q3 2016 in Review

Affinity Investment Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 44,903 shares — an estimated $6.34M sold.

Affinity Investment Advisors first reported a position in JAZZ in Q3 2014 and held it in 8 quarters. The position peaked at $6.34M in Q2 2016. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

Affinity Investment Advisors reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Affinity Investment Advisors sold 44,903 Jazz Pharmaceuticals shares in Q3 2016, an estimated $6.34M.
Affinity Investment Advisors first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 8 quarters.
Affinity Investment Advisors's Jazz Pharmaceuticals position peaked at $6.34M in Q2 2016.
325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on Affinity Investment Advisors's 13F filing for Q3 2016, filed 7 Nov 2016.